← Back to Clinical Trials
Recruiting NCT03442465

NCT03442465 Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03442465
Status Recruiting
Phase
Sponsor Memorial Sloan Kettering Cancer Center
Condition Bone Sarcoma
Study Type OBSERVATIONAL
Enrollment 300 participants
Start Date 2018-02-14
Primary Completion 2027-02-14

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Toronto Extremity Salvage ScoreMusculoskeletal Tumor Society ScoreTimed Get Up and Go Test

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 300 participants in total. It began in 2018-02-14 with a primary completion date of 2027-02-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to look at the amount of function that returns in participants that have reconstruction with bone graft or artificial device and in participants who have tumor surgery plus regenerative osseous surgery. The study will look at the level of function for a period of 3 years after the surgery. Another purpose of this study is to look at how well the bone heals in participants undergoing regenerative surgery

Eligibility Criteria

Inclusion Criteria: * All patients undergoing reconstructive surgery for neoplasms involving bone on the orthopaedic surgery service at MSK * Current or prior history of primary neoplasms involving osseous structures, including all subtypes * Confirmation of diagnosis that has been performed by the MSK's Department of Pathology via direct review of tissue/slides * Patients must read and understand English * Age \>/=4 * Patients must read and understand English Exclusion Criteria: * Patients that weight \<17 kilograms

Contact & Investigator

Central Contact

Daniel Prince, MD, MPH

✉ princed@mskcc.org

📞 212-639-6488

Principal Investigator

Daniel Prince, MD

PRINCIPAL INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Frequently Asked Questions

Who can join the NCT03442465 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, studying Bone Sarcoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03442465 currently recruiting?

Yes, NCT03442465 is actively recruiting participants. Contact the research team at princed@mskcc.org for enrollment information.

Where is the NCT03442465 trial being conducted?

This trial is being conducted at Basking Ridge, United States, Middletown, United States, Harrison, United States, New York, United States and 1 additional location.

Who is sponsoring the NCT03442465 clinical trial?

NCT03442465 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Daniel Prince, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 300 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology